Literature DB >> 31656669

Repair versus replacement of mitral valves in cases of severe rheumatic mitral stenosis: mid-term clinical outcomes.

Yuqing Jiao1, Tiange Luo1, Haibo Zhang1, Jie Han1, Yan Li1, Yixin Jia1, Shuai Zheng1, Xu Meng1.   

Abstract

BACKGROUND: We compared and analyzed differences between repair vs. replacement of mitral valves on severe rheumatic mitral stenosis by looking at mid-term clinical outcomes.
METHODS: Patients with severe rheumatic mitral stenosis (mitral valve area ≤1.5 cm2, with or without mitral valve regurgitation) from January 2011 to September 2017 were divided into two groups: a mitral valve repair group (MVP) and a mitral valve replacement group (MVR). After propensity score matching between the two groups, we compared changes in post-operation clinical outcomes. We also monitored changes in left ventricular longitudinal and circumferential strain in successfully matched patients (20 pairs) by echocardiography speckle tracing.
RESULTS: A total of 921 patients were recruited (221 in MVP and 700 in MVR). After a propensity score matching, 216 cases were selected with 108 patients in each group. With a follow-up period of 3 months to 7.1 years, the incidence of heart failure was observed to be significantly higher in the MVR group than in the MVP group (P<0.05). Echocardiographic speckle tracking imaging analysis showed that left ventricular longitudinal strain decreased in the MVR group, suggesting that a change of cardiac structure may affect the cardiac function.
CONCLUSIONS: Selecting suitable patients for mitral valve repair is feasible even for patients with severe rheumatic mitral stenosis. In our study, compared with prosthetic valve replacement in these patients, valve repair still significantly reduced the valve-related complications rates and improved the quality of life during the follow-up. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Rheumatic; follow-up studies; mitral stenosis; mitral valve repair; mitral valve replacement

Year:  2019        PMID: 31656669      PMCID: PMC6790454          DOI: 10.21037/jtd.2019.08.101

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

Review 1.  The structure and function of the helical heart and its buttress wrapping. IV. Concepts of dynamic function from the normal macroscopic helical structure.

Authors:  G D Buckberg; C Clemente; J L Cox; H C Coghlan; M Castella; F Torrent-Guasp; M Gharib
Journal:  Semin Thorac Cardiovasc Surg       Date:  2001-10

2.  Basic science review: the helix and the heart.

Authors:  Gerald D Buckberg
Journal:  J Thorac Cardiovasc Surg       Date:  2002-11       Impact factor: 5.209

3.  Guidelines for reporting mortality and morbidity after cardiac valve interventions.

Authors:  Cary W Akins; D Craig Miller; Marko I Turina; Nicholas T Kouchoukos; Eugene H Blackstone; Gary L Grunkemeier; Johanna J M Takkenberg; Tirone E David; Eric G Butchart; David H Adams; David M Shahian; Siegfried Hagl; John E Mayer; Bruce W Lytle
Journal:  J Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 5.209

4.  Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries.

Authors:  Christina M Vassileva; Gregory Mishkel; Christian McNeely; Theresa Boley; Stephen Markwell; Steven Scaife; Stephen Hazelrigg
Journal:  Circulation       Date:  2013-04-08       Impact factor: 29.690

5.  Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation.

Authors:  G T Wilkins; A E Weyman; V M Abascal; P C Block; I F Palacios
Journal:  Br Heart J       Date:  1988-10

6.  Is rheumatic mitral valve repair still a feasible alternative?: indications, technique, and results.

Authors:  Ihsan Bakir; Burak Onan; Ismihan Selen Onan; Mehmet Gul; Nevzat Uslu
Journal:  Tex Heart Inst J       Date:  2013

7.  Mitral Valve Surgery for Rheumatic Lesions in Young Patients.

Authors:  B Cardoso; P Loureiro; I Gomes; A Gordo; N Banazol; I Fragata; C Trigo; F Pinto; José Fragata
Journal:  World J Pediatr Congenit Heart Surg       Date:  2016-05

8.  Features of rheumatic mitral valves and a grading system to identify suitable repair cases in China.

Authors:  Tiange Luo; Jie Han; Xu Meng
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

9.  Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion.

Authors:  Masanori Hirota; Tadashi Isomura; Chieko Katsumata; Fusahiko Ito; Masazumi Watanabe
Journal:  J Cardiothorac Surg       Date:  2016-05-10       Impact factor: 1.637

10.  Predicting Left Ventricular Dysfunction after Surgery in Patients with Chronic Mitral Regurgitation: Assessment of Myocardial Deformation by 2-Dimensional Multilayer Speckle Tracking Echocardiography.

Authors:  Eun Jeong Cho; Sung-Ji Park; Hye Rim Yun; Dong Seop Jeong; Sang-Chol Lee; Seung Woo Park; Pyo Won Park
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

View more
  4 in total

1.  A Novel Rheumatic Mitral Valve Disease Model with Ex Vivo Hemodynamic and Biomechanical Validation.

Authors:  Matthew H Park; Pearly K Pandya; Yuanjia Zhu; Danielle M Mullis; Hanjay Wang; Annabel M Imbrie-Moore; Robert Wilkerson; Mateo Marin-Cuartas; Y Joseph Woo
Journal:  Cardiovasc Eng Technol       Date:  2022-08-08       Impact factor: 2.305

2.  Clinical outcomes following surgical mitral valve repair or replacement in patients with rheumatic heart disease: a meta-analysis.

Authors:  Yefan Jiang; Chen Wang; Geng Li; Si Chen
Journal:  Ann Transl Med       Date:  2021-02

3.  Altered Expression of Transfer-RNA-Derived Small RNAs in Human With Rheumatic Heart Disease.

Authors:  Zhao-Yu Yang; Peng-Fei Li; Zhi-Qing Li; Tao Tang; Wei Liu; Yang Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-01

4.  Clinico-pathological classification of rheumatic mitral valve damage and surgical strategy.

Authors:  Tiange Luo; Xu Meng
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.